Evotec AG has expanded its collaboration with MedImmune after reaching a key milestone, triggering a payment of $653,000. MedImmune has been granted a commercial license and the companies will extend their diabetes and beta cell regeneration collaboration through 2013.   Under the agreement, MedImmune has exclusive access to a defined set of biologic targets that have the potential to prevent or reverse disease progression in diabetic patients. Evotec will receive additional research payments to...